An open-label, single-arm, phase2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
Ravi Vij, Michael Wang, Jonathan L. Kaufman, Sagar Lonial, Andrzej J. Jakubowiak, A. Keith Stewart, Vishal Kukreti, Sundar Jagannath, Kevin T. McDonagh, Melissa Alsina, Nizar J. Bahlis, Frederic J. Reu, Nashat Y. Gabrail, Andrew Belch, Jeffrey V. Matous, Peter Lee, Peter Rosen, Michael Sebag, David H. Vesole, Lori A. KunkelSandra M. Wear, Alvin F. Wong, Robert Z. Orlowski, David S. Siegel
Research output: Contribution to journal › Article › peer-review
241Scopus
citations
Fingerprint
Dive into the research topics of 'An open-label, single-arm, phase2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma'. Together they form a unique fingerprint.